Abstract
Mouse leukemia models were a central component of the initial drug discovery programs employed by the Division of Cancer Treatment (DCT) of the National Cancer Institute (NCI) during the early 1960s and 1970s. The L1210 and P388 leukemias, developed in 1948 (1) and 1955 (2), respectively, played a major role in both screening and detailed evaluations of candidate anticancer agents. Today, 40 yr later, these models are still used to evaluate anticancer activity, although at a greatly reduced level, and to study mechanisms of drug resistance. This chapter reviews their past contributions, updates their present role in the evaluation of anticancer drugs, and summarizes data for the drug sensitivity of these two leukemias and various drug-resistant P388 sublines to clinically useful drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Law LW, Dunn DB, Boyle PJ, Miller JH. Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice. J Natl Cancer Inst 1949; 10: 179–192.
Dawe CJ, Potter M. Morphologic and biologic progression of a lymphoid neoplasm of the mouse in vivo and in vitro. Am J Pathology 1957; 33 (3): 603.
Griswold DP Jr, Harrison SD Jr. Tumor models in drug development. Cancer Metastasis Rev 1991; 10: 255–261.
Zubrod CG. Historic milestone in curative chemotherapy. Semin Oncol 1979; 6 (4): 490–505.
Goldin A, Serpick AA, Mantel N. A commentary, experimental screening procedures and clinical predictability value. Cancer Chemother Rep 1966;. 50(4):173–218.
Carter S. Anticancer drug development progress: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe. Natl Cancer Inst Monogr 1974; 40: 31–42.
Goldin A, Venditti JM, Muggia FM, Rozencweig M, DeVita VT. New animal models in cancer chemotherapy. In: Fox 13W, ed. Advances in Medical Oncology, Research and Education. Vol 5. Basis for Cancer Therapy 1. Pergamon Press, New York, NY, 1979: 113–122.
Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589–601.
Boyd D. Budget cuts to force early end of P388 screening, DTP’s, Boyd says. The Cancer Letter 1987; 13 (2): 5–7.
Skipper HE, Schabel FM Jr, Wilcox WS, Laster WR Jr, Trader MW, Thompson SA. Experimental evaluation of potential anticancer agents. XVII. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. Cancer Chemother Rep 1965; 47: 41–64.
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1977; 1: 411–435.
Lloyd HH. Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM, eds. Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells. Williams & Wilkins, Baltimore, MD, 1977, pp. 455–469.
Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep 1967; 51: 1625–1655.
Corbett TH, Valeriote FA, Baker LH. Is the P388 murine tumor no longer adequate as a drug discovery model? Investig New Drugs 1987; 5: 3–20.
Staquet MJ, Byar DP, Green SB, Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 1983; 67: 753–765.
Trader MW, Harrison SD Jr, Laster WR Jr, Griswold DP Jr. Cross-resistance and collateral sensitivity of drug-resistant P388 and L1210 leukemias to flavone acetic acid (FAA, NSC 347512) in vivo (Abstr). Proc AACR 1987; 28: 312.
Wilkoff LJ, Dulmadge EA. Sensitivity of proliferating cultured murine pancreatic tumor cells to selected antitumor agents. J Natl Cancer Inst 1986; 77 (5): 1163–1169.
Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 1983; 67: 905–922 (see correction, Cancer Treat Rep 1984; 68:453–459).
Waud WR, Griswold DP Jr. Therapeutic resistance in leukemia. In: Teicher BA, ed. Drug Resistance in Oncology. Marcel Dekker, Inc., New York, NY,1993, pp. 227–250.
Waud WR. Murine L1210 and P388 leukemias. In: Teicher B, ed. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press, Totowa, NJ, 1997, pp. 59–74.
Ho AD, Seither E, Ma DDF, Prentice G. Mitoxantrone-induced toxicity and DNA strand breaks in leukemic cells. Br J Haematol 1987; 65: 51–55.
Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4’-(9-acridinylamino)methanesulfon-m-anisidide. Proc Natl Acad Sci USA 1984; 81: 1361–1365.
Rose WC, Huftalen JB, Bradner WT, Schurig JE. In vivo characterization of P388 leukemia resistant to mitomycin C. In Vivo 1987; 1: 47–52.
Eng WK, McCabe FL, Tan KB, Mattere MR, Hofmann GA, Woessner RD, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990; 38: 471–480.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dykes, D.J., Waud, W.R. (2002). Murine L1210 and P388 Leukemias. In: Teicher, B.A. (eds) Tumor Models in Cancer Research. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-100-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-59259-100-8_2
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6883-1
Online ISBN: 978-1-59259-100-8
eBook Packages: Springer Book Archive